Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TMC Angiomax Launch Projected For Mid-2001 With Innovex Sales Force

Executive Summary

The Medicines Company expects to launch its anticoagulant Angiomax (bivalirudin) by mid-2001 with the help of Quintiles' contract sales division Innovex.

You may also be interested in...



Quintiles' Stake In NitroMed Is First Co-Investment With Care Capital

Quintiles' stake in nitric oxide-based medicines company NitroMed represents one of two initial co-investments under a strategic alliance with venture capital firm Care Capital.

Quintiles' Stake In NitroMed Is First Co-Investment With Care Capital

Quintiles' stake in nitric oxide-based medicines company NitroMed represents one of two initial co-investments under a strategic alliance with venture capital firm Care Capital.

Quintiles To Invest $50-$100 Mil. In "Non-Traditional" Outsourcing Deals

Quintiles plans to invest $50 mil. to $100 mil. in risk-sharing and other "non-traditional" outsourcing deals over the next several years, CEO Dennis Gillings, PhD, told investors at the company's Investor Day Conference in New York City Nov. 30.

Related Content

UsernamePublicRestriction

Register

PS036508

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel